

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number  
**WO 2004/089342 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 9/20**,  
31/4439, 9/28

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(21) International Application Number:  
PCT/EP2004/050493

(22) International Filing Date: 8 April 2004 (08.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
103 17 023.5 11 April 2003 (11.04.2003) DE  
03008453.7 11 April 2003 (11.04.2003) EP

(71) Applicant (for all designated States except US): **ALTANA PHARMA AG** [DE/DE]; Byk-Gulden-Str. 2, 78467 Konstanz (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DIETRICH, Rango** [DE/DE]; Im Tiergarten 16, 78465 Konstanz (DE). **NEY, Hartmut** [DE/DE]; Peter-Thumb-Str. 46, 78464 Konstanz (DE). **HILTL, Simone** [DE/DE]; Clara-Schumann-Str. 8, 78464 Konstanz (DE). **HAAS, Bernd-Michael** [DE/DE]; In der Abtswiese 22, 78479 Reichenau (DE).

(74) Agent: **RUPP, Herbert**; c/o Altana Pharma AG, Byk-Gulden-Str. 2, 78467 Konstanz (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

**Published:**

— with international search report

(88) Date of publication of the international search report:  
10 March 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ORAL PHARMACEUTICAL PREPARATION COMPRISING A PROTON PUMP ANTAGONIST AND A BASIC EXIPIENT

(57) Abstract: The invention relates to novel dosage forms for proton pump antagonists.

WO 2004/089342 A3

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K9/20 A61K31/4439 A61K9/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/45693 A (BYK GULDEN LOMBERG CHEM FAB ; LINDER RUDOLF (DE); NEY HARTMUT (DE); DI) 13 June 2002 (2002-06-13) cited in the application page 44, line 9 - page 46, line 6 examples 27-29 page 40, paragraph 5 page 41, paragraph 2 page 42, paragraph 3 example N	1-26
X	DE 199 25 710 A (BYK GULDEN LOMBERG CHEM FAB) 14 December 2000 (2000-12-14)	1-16, 22-26
Y	column 3, line 40 - line 63 column 4, line 23 - line 28 column 4, line 60 - line 68 examples column 5, line 18 - line 25	17-21
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the international search

2 December 2004

Date of mailing of the international search report

10/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Giménez Miralles, J

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/74654 A (BYK GULDEN LOMBERG CHEM FAB ; LINDER RUDOLF (DE); DIETRICH RANGO (DE)) 14 December 2000 (2000-12-14)	1-16, 22-26
Y	page 6, paragraph 6 - page 7, paragraph 4 examples	17-21
X	US 2002/045646 A1 (PHILLIPS JEFFREY O) 18 April 2002 (2002-04-18)	1-16, 22-26
Y	paragraphs '0036!, '0037!, '0085! - '0090!, '0278!, '0394!, '0398! - '0403!, '0418! - '0432!, '0436! - '0446! Tablet D3, example I table 8	17-21
P,X	US 2004/028737 A1 (DESHMUKH SATISH RAMACHANDRA ET AL) 12 February 2004 (2004-02-12) examples 3,4	1-16, 22-26
X	EP 1 222 922 A (EISAI CO LTD) 17 July 2002 (2002-07-17)	1-16, 22-26
Y	examples 4-8; table 2	17-21
X	US 6 299 904 B1 (SHIMIZU TOSHIHIRO ET AL) 9 October 2001 (2001-10-09)	1-16, 22-26
Y	column 6, line 65 - column 7, line 34 example 5	17-21
X	US 4 786 505 A (ODA MINORU ET AL) 22 November 1988 (1988-11-22)	1-16, 22-26
Y	examples 9,10	17-21
X	WO 98/50019 A (CHEN JIVN REN ; SAGE PHARMACEUTICALS INC (US)) 12 November 1998 (1998-11-12)	1-16, 22-26
Y	examples	17-21
X	WO 00/78284 A (LAHAV RAFFAEL ; AZOULAY VALERIE (IL); DEXCEL LTD (IL)) 28 December 2000 (2000-12-28)	1-16, 22-26
Y	examples 1,4,10,13	17-21

# INTERNATIONAL SEARCH REPORT

ational application No.  
PCT/EP2004/050493

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-26 partly  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 1-26 partly

Present independent claim 1 relates to an extremely large number of possible oral dosage forms, namely all those comprising: 1) a reversible PPI ("proton pump antagonist" or APA), and 2) a basic excipient, with no restriction or limitation, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such dosage forms, namely film-coated immediate release tablets comprising soraprazan (as defined in claim 18) and a basic compound as defined in claims 15 and 16. Other possibilities are not sufficiently disclosed in the application. In particular, it is not proved that the stabilising effect is also achieved for other APAs different from soraprazan. The area covered by the claims is broader than justified by the extent of the disclosure. It follows that the claims so lack support, and/or the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. It is the same for independent claims 22 and 23.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the dosage form by reference to the result to be achieved, expressed in terms of parameters (disintegration rate; see claims 3, 6-10 and 23-25), which only amounts to claiming the technical problem to be solved instead of claiming the relevant technical features which amount to its solution. This lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to claim 1 taken in combination with claims 5, 15 and 16, and 18, as interpreted in connection with the description and the examples.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0245693	A	13-06-2002	AU 1607302 A	18-06-2002
			BR 0115987 A	23-12-2003
			CA 2430828 A1	13-06-2002
			CZ 20031881 A3	14-04-2004
			EE 200300235 A	15-08-2003
			WO 0245693 A1	13-06-2002
			EP 1341527 A1	10-09-2003
			HU 0400566 A2	28-06-2004
			JP 2004514736 T	20-05-2004
			NO 20032593 A	05-08-2003
			US 2004058896 A1	25-03-2004
DE 19925710	A	14-12-2000	DE 19925710 A1	14-12-2000
WO 0074654	A	14-12-2000	AU 775995 B2	19-08-2004
			AU 5074100 A	28-12-2000
			BG 106165 A	30-09-2002
			BR 0011347 A	19-03-2002
			CA 2376202 A1	14-12-2000
			CN 1361683 T	31-07-2002
			CZ 20014405 A3	17-04-2002
			EE 200100660 A	15-04-2003
			WO 0074654 A1	14-12-2000
			EP 1187601 A1	20-03-2002
			HR 20020006 A1	30-04-2003
			HU 0201637 A2	28-11-2002
			JP 2003501377 T	14-01-2003
			MX PA01012659 A	04-09-2003
			NO 20015980 A	23-01-2002
			PL 352882 A1	22-09-2003
			SK 18022001 A3	04-04-2002
			TR 200103527 T2	22-04-2002
			ZA 200110000 A	03-10-2002
US 2002045646	A1	18-04-2002	US 6489346 B1	03-12-2002
			US 5840737 A	24-11-1998
			BR 0210971 A	24-08-2004
			CA 2453117 A1	06-02-2003
			EP 1414452 A1	06-05-2004
			JP 2004521955 T	22-07-2004
			WO 03009846 A1	06-02-2003
			US 2003191159 A1	09-10-2003
			US 2004048896 A1	11-03-2004
			US 2004171646 A1	02-09-2004
			AU 3276701 A	24-07-2001
			BR 0107565 A	11-02-2003
			CA 2396159 A1	19-07-2001
			EP 1246622 A1	09-10-2002
			EP 1430895 A1	23-06-2004
			JP 2003519656 T	24-06-2003
			MX PA02006780 A	06-10-2003
			NO 20023313 A	30-08-2002
			PL 357144 A1	12-07-2004
			WO 0151050 A1	19-07-2001
			US 2003118669 A1	26-06-2003
			US 2003144306 A1	31-07-2003
			US 2003215527 A1	20-11-2003
			US 2004058018 A1	25-03-2004

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002045646	A1	ZA 200205512 A AU 1907100 A WO 0026185 A2	10-02-2004 22-05-2000 11-05-2000
US 2004028737	A1	12-02-2004	NONE
EP 1222922	A	17-07-2002	AU 7950200 A 30-04-2001 CA 2387746 A1 26-04-2001 EP 1222922 A1 17-07-2002 HU 0203333 A2 28-02-2003 NO 20021875 A 04-06-2002 CN 1382049 T 27-11-2002 WO 0128559 A1 26-04-2001
US 6299904	B1	09-10-2001	AT 209898 T 15-12-2001 AU 7451198 A 30-12-1998 CA 2286753 A1 03-12-1998 CN 1130194 B 10-12-2003 DE 69802810 D1 17-01-2002 DE 69802810 T2 18-04-2002 EP 0996424 A1 03-05-2000 ES 2164424 T3 16-02-2002 WO 9853798 A1 03-12-1998 JP 11043429 A 16-02-1999 TW 580397 B 21-03-2004 US 2001009678 A1 26-07-2001
US 4786505	A	22-11-1988	GB 2189698 A 04-11-1987 SG 154294 G 17-03-1995 AR 240250 A1 30-03-1990 AT 84215 T 15-01-1993 AT 140387 T 15-08-1996 AT 184482 T 15-10-1999 AU 601974 B2 27-09-1990 AU 7191287 A 05-11-1987 CA 1292693 C 03-12-1991 CN 87103284 A , B 11-11-1987 CY 1810 A 20-10-1995 DD 273197 A5 08-11-1989 DE 3751860 D1 22-08-1996 DE 3751860 T2 21-11-1996 DE 3783394 D1 18-02-1993 DE 3783394 T2 06-05-1993 DE 247983 T1 27-09-1990 DK 215887 A 31-10-1987 EP 0247983 A2 02-12-1987 EP 0496437 A2 29-07-1992 EP 0567201 A2 27-10-1993 ES 2006457 T3 01-01-1994 ES 2091971 T3 16-11-1996 ES 2135443 T3 01-11-1999 FI 871913 A , B, 31-10-1987 GR 89300058 T1 22-06-1989 GR 3007434 T3 30-07-1993 GR 3020734 T3 30-11-1996 GR 3032101 T3 31-03-2000 HK 52897 A 02-05-1997 HK 135294 A 09-12-1994

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4786505	A		HR 920854 A1	31-10-1994
			HU 43954 A2	28-01-1988
			IE 61416 B1	02-11-1994
			JP 1863556 C	08-08-1994
			JP 62258320 A	10-11-1987
			JP 5069807 B	01-10-1993
			JP 2740993 B2	15-04-1998
			JP 5294831 A	09-11-1993
			KR 9104579 B1	06-07-1991
			LT 1683 A ,B	25-07-1995
			LV 10357 A ,B	20-02-1995
			LV 5760 A4	20-12-1996
			NO 871790 A ,B,	02-11-1987
			NZ 220096 A	26-04-1990
			PH 25701 A	18-09-1991
			PL 265416 A1	21-07-1988
			PT 84785 A ,B	01-05-1987
			SI 8710681 A8	31-10-1996
			SU 1820837 A3	07-06-1993
		WO 9850019	A	12-11-1998
JP 2001524131 T	27-11-2001			
TW 550090 B	01-09-2003			
WO 9850019 A1	12-11-1998			
US 2001006649 A1	05-07-2001			
US 2003203018 A1	30-10-2003			
WO 0078284	A	28-12-2000	AU 5423200 A	09-01-2001
			CA 2377605 A1	28-12-2000
			EP 1187599 A1	20-03-2002
			WO 0078284 A1	28-12-2000